Corporate and M&A

  • EssilorLuxottica logo

    EssilorLuxottica sees first signs of recovery


    EssilorLuxottica is seeing the “first signs of recovery” as lockdowns introduced worldwide to slow down the spread of the Covid-19 pandemic are lifted. In a prepared message delivered to shareholders at the company’s annual general meeting, the executive chairman Leonardo Del Vecchio and executive vice-chairman Hubert Sagnières ...

  • Rodenstock

    Rodenstock completes a €75 million capital increase


    Rodenstock  has obtained funds from its shareholders to finance its development while its business is recovering faster than expected from the coronavirus crisis.

  • Article

    CooperVision sees Q3 sales fall after 17% decline in Q2


    CooperVision (CVI)’s sales in the second quarter ended on April 30 fell by 17 percent to $402.2 million, as the business highlighted “unprecedented” challenges tied to Covid-19 and the management warned that third-quarter sales could contract by 15 to 20 percent. The parent company CooperCompanies withdrew its full-year guidance ...

  • marcolin eyewear

    ​Marcolin Q1 sales drop by 28% on Covid-19 impact


    In the first quarter of 2020, Marcolin ’s revenues fell by 28.0 percent to €93.5 million due to the impact of the Covid-19 pandemic. At constant currency rates, the decline reached 28.6 percent. In January and February, the company was moderately affected by the shutdown of its Chinese suppliers, ...

  • Italia Independent logo

    Italia Independent lowers its forecasts until 2023


    Italia Independent has revised downwards its business plan though 2023 due to the impact of the Covid-19 pandemic. It now expects to post sales of about €40 million in 2023 compared with a previous estimate of €42 million in the business plan approved in November 2019. The revenues are ...

  • Article

    Zeiss claims a higher market position in eyeglass lenses


    In reporting its results for the first half of its financial year, ended on March 31, Carl Zeiss said it expanded its position in the market for eyeglass lenses. Without breaking down the figures, it said that the Vision Care division saw growth during the period, but gave no ...

  • Article

    Richemont enjoys strong demand in China but warns that Covid-19 impact may last


    As China has become the bellwether on how fast an economy can recover from the Covid-19 crisis, Richemont pointed out that it is currently enjoying strong demand in the country. Nevertheless, it warned that the impact of the virus on the global economy may last a long time.

  • Article

    Bausch Health’s Q1 revenues flat


    Bausch Health ’s sales were constrained by the Covid-19 pandemic but the global consumer and international prescription activities of its Bausch + Lomb eye care division posted strong growth. It expects a recovery from the latter part of the second quarter but nevertheless cut its full-year guidance.

  • Article

    Hoya Q4 eyeglass lens sales down 10%, contact lenses more resilient


    Like many others, the Covid-19 outbreak has hit Hoya Corporation in its quarterly results. The Japanese group is, however, upbeat on the prospect of recouping from pent-up demand in the eyeglass segment based on signals from China and South Korea, where the pandemic is vaning.

  • Article

    Eschenbach in full swing on home turf


    Eschenbach has been growing constantly in Germany, becoming the market leader in prescription eyewear. It has also enjoyed strong growth in Europe and the U.S..

  • Article

    Fedon raises €5 million in financing


    Giorgio Fedon , the Italian producer of eyeglass cases, obtained €5 million in financing from two leading Italian banks, as well as some members of the family that control it, to fund its investments. In 2019, it returned to being profitable, albeit marginally.

  • EssilorLuxottica_Lenses

    EssilorLuxottica’s Q1 sales drop by 10%


    EssilorLuxottica ’s first-quarter revenues were down by 10.1 percent from the year-ago quarter to €3,784 million, or by 10.9 percent in constant currencies, due to the impact of the Covid-19 pandemic. But, the company is confident that pent-up demand will underpin sales when the crisis is over. Thanks to its ...

  • logo-fielmann

    Fielmann’s Q1 sales and profits decline


    (updated) Blaming the coronavirus outbreak, Fielmann reported a sharp 74.8 percent drop in net income for the first quarter of 2020, down to €11.8 million, on a 7.0 percent decline in consolidated revenues to €352.9 million for the first quarter of this year. The number of glasses sold fell ...

  • Article

    Fielmann posts slightly higher profits for the year


    Fielmann ’s performance for 2019 seems to have confirmed the positive momentum that it had already reported for the first half of the year. According to preliminary figures, its consolidated sales for the 2019 financial year show an increase of about 6 percent to €1.52 billion as compared to €1.43 ...

  • Article

    Higher sales and profits for Synsam


    The Synsam Group reached a turnover of 3,741 million Swedish kronor (€350.7m-$387.4m) last year, up from SEK 3,380 million in 2018. The adjusted operating profit amounted to SEK 984 million (€92.3m-$101.9m) a big increase from SEK 643 million in the previous year. In addition to the opening of new ...

  • Article

    Hoya reports a squeeze in segment sales and profits


    The results of Hoya Corp. for the third quarter ended on Dec. 31 were negatively impacted by the expected increase in the sales tax in Japan, which had increased purchases in the previous quarter. In particular, sales of contact lenses and eyeglass lenses declined in the country, affecting also the ...

  • Article

    Alcon’s first year after Novartis spin-off is a success


    Alcon reported total sales of $7,362 million for the full year 2019, an increase of 3 percent on a reported basis and 5 percent in constant currencies. The management said that 2019 was a good year for the company, as it completed its spin-off from Novartis to become an ...

  • Article

    Lawsuit widens Bausch Health’s net loss in Q4


    Bausch Health reported a net loss of $1,516 million for the fourth quarter, compared with a net loss of $344 million for the year-ago period. The management blamed mainly the accrual of legal reserves established for the resolution of a so-called “stock drop” litigation in the U.S. linked to the ...

  • Article

    EssilorLuxottica posts strong sales and profits for 2019


    In 2019, the first full year in which Essilor and Luxottica were part of the same company, EssilorLuxottica – alias Essilux – enjoyed a 7.4 percent jump in revenues to €17.390 million on a pro-forma basis. In constant currencies, they grew by 4.4 percent. One of the highlights was a ...